,trastuzumab deruxtecan
roche,astrazeneca,daiichi sankyo
['trastuzumab', 'mbc', 'destiny-breast03', 'breast', 'astrazeneca']
join as she presents deruxtecan versus trastuzumab emtansine in patients with her2-positive unresectable and/or metastatic breast cancer: safety follow-up of the randomized, ph iii study destiny-breast03. hall d1 at 1:15 pm #asco22 #mbc 
Creating Aha! Moments In Healthcare
IDEOlogy Health is leading the change in how healthcare professionals connect and stay up-to-date on the latest advancements